Data updated: Mar 10, 2026
PENICILLIN V POTASSIUM
PENICILLIN V POTASSIUM
Approved 1971-11-17
10
Indications
--
Phase 3 Trials
54
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1971-11-17
- Routes
- ORAL
- Dosage Forms
- FOR SOLUTION, TABLET
Companies
CHARTWELL RX Novartis Aurobindo Pharma Hikma PUREPAC PHARM IVAX SUB TEVA PHARMS Viatris BELCHER PHARMS
Active Ingredient: PENICILLIN V POTASSIUM
Website: ↗
PENICILLIN V POTASSIUM Approval History
Loading approval history...
What PENICILLIN V POTASSIUM Treats
10 FDA approvalsOriginally approved for its first indication in 1971 . Covers 10 distinct patient populations.
- Other (10)
Other
(10 approvals)- • Approved indication (Nov 1971)
- • Approved indication (Nov 1971)
- • Approved indication (Aug 1972)
- • Approved indication (Oct 1976)
- • Approved indication (Nov 1988)
- • Approved indication (Nov 1988)
- • Approved indication (Feb 1989)
- • Approved indication (Nov 1995)
- • Approved indication (Apr 2008)
- • Approved indication (Oct 2013)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PENICILLIN V POTASSIUM FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.